China Medical System Holdings Ltd
SWB:2M7C
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.795
1.66
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
China Medical System Holdings Ltd
Interest Income Expense
China Medical System Holdings Ltd
Interest Income Expense Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
China Medical System Holdings Ltd
SWB:2M7C
|
Interest Income Expense
¥269.2m
|
CAGR 3-Years
217%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
G
|
Grand Pharmaceutical Group Ltd
HKEX:512
|
Interest Income Expense
HK$392.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
54%
|
CAGR 10-Years
N/A
|
|
|
U
|
United Laboratories International Holdings Ltd
HKEX:3933
|
Interest Income Expense
¥240.7m
|
CAGR 3-Years
157%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Sino Biopharmaceutical Ltd
HKEX:1177
|
Interest Income Expense
¥2.8B
|
CAGR 3-Years
-43%
|
CAGR 5-Years
49%
|
CAGR 10-Years
18%
|
|
|
C
|
China Resources Pharmaceutical Group Ltd
HKEX:3320
|
Interest Income Expense
-HK$1.1B
|
CAGR 3-Years
5%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
|
H
|
HUTCHMED (China) Ltd
HKEX:13
|
Interest Income Expense
$513.2m
|
CAGR 3-Years
116%
|
CAGR 5-Years
64%
|
CAGR 10-Years
31%
|
|
China Medical System Holdings Ltd
Glance View
China Medical System Holdings Ltd., a prominent player in the pharmaceutical industry, weaves its business model around the intricate pathway of driving market expansion through innovation and strategic partnerships. Founded with a vision to bring cutting-edge and specialized medicines to the Chinese healthcare market, CMS has established itself as a stalwart distributor and marketer. The company operates by obtaining licenses and distribution rights for pharmaceutical products primarily from European and North American manufacturers. By leveraging these international partnerships, CMS effectively bridges the gap between Western innovation and Chinese demand, tailoring its portfolio to include niche and differentiated therapeutic products that cater to the evolving needs of China's healthcare landscape. At the core of CMS's revenue model lies its proficiency in brand building and market penetration. Unlike the conventional pharmaceutical giants focusing solely on R&D, CMS maximizes its profits through strategic marketing and efficient distribution networks. By prioritizing products that require expert promotion to healthcare professionals, CMS utilizes its extensive sales force to ensure these products gain maximum visibility and acceptance in the marketplace. This business model not only fosters a symbiotic relationship with international pharmaceutical partners but also sustains a robust pipeline of new offerings. Therefore, with a strategic balancing act between global pharmaceutical expertise and local market intricacies, China Medical System Holdings Ltd. continues to fortify its position as a pivotal conduit in the dissemination of specialized medical solutions across China.
See Also
What is China Medical System Holdings Ltd's Interest Income Expense?
Interest Income Expense
269.2m
CNY
Based on the financial report for Jun 30, 2025, China Medical System Holdings Ltd's Interest Income Expense amounts to 269.2m CNY.
What is China Medical System Holdings Ltd's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
23%
Over the last year, the Interest Income Expense growth was 12%. The average annual Interest Income Expense growth rates for China Medical System Holdings Ltd have been 217% over the past three years , 23% over the past five years .